Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Polycystic Ovary Syndrome 1Insulin Resistance 1Hyperandrogenism 1Glucose Intolerance 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Anovulation 1

Interventions

pembrolizumab 69Nivolumab 67cabozantinib 45Ipilimumab 36Specimen Handling 32Magnetic Resonance Spectroscopy 32lenvatinib 26Axitinib 25belzutifan 21Sunitinib 17Biopsy 15Radiosurgery 14CTLA-4 Antigen 13atezolizumab 12Everolimus 10pazopanib 8fludarabine 8avelumab 8Bevacizumab 8toripalimab 7cemiplimab 7Nephrectomy 7Immunoglobulin G 7Cyclophosphamide 7aldesleukin 6Standard of Care 6Radiotherapy 6Blood Specimen Collection 6spartalizumab 5palbociclib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Inulin × 1 year × Clear all
NCT06866262 2025-09-09

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

University of Michigan Rogel Cancer Center

Phase 1/2 Recruiting
55 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡